$21.56
-1.7%Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
Chief Executive Officer
Executive Vice President of Strategy & Business Development
Compensation
$1,131,324
President of Enovis International Surgical
President of U.S. Surgical and Global Product & Enabling Technologies
Senior Vice President & Chief Financial Officer
Compensation
$988,719
Senior Vice President & Chief Human Resources Officer
Compensation
$896,341
Senior Vice President & Chief Legal Officer
Compensation
$874,354
Vice President of Corporate Communication
Vice President of Investor Relations
Vice President, Controller & Chief Accounting Officer
During the last 12 months, insiders have purchased $901K and sold $43K worth of ENOV shares, resulting in $857K of net buying activity.
4.5K
105.52K
0
0.00
+106K
+$106K
2.3K
56.55K
666
18.12K
+38K
+$38K
8.9K
274.80K
0
0.00
+275K
+$275K
15.7K
463.79K
958
25.35K
+438K
+$438K
Pryor Daniel A
Officer: Evp, Strategy & Business Dev.
$289K
Mcdonald Damien
Director, Officer: Chief Executive Officer
$200K
Engert Oliver
Officer: Chief Administrative Officer
$162K
Tandy Bradley J
Officer: Svp And Chief Legal Officer
$101K
Kleckner John
Officer: Principal Accounting Officer
$75K
Pryor Daniel A
Other: Former Evp, Strategy & Bus Dev
$18K
Vogt Louis
Officer: Group President, Recon
$12K
Ross Terry D
Officer: Group President, P&R
$9K
Kleckner John
Officer: Principal Accounting Officer
$5K
Strong bullish signal with $857K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
5 insider buyers vs. 4 sellers. More insiders buying than selling indicates positive sentiment.
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
ENOV - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 06, 2026 | April 06, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 11, 2025 | May 21, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 05, 2024 | May 20, 2024 | 2024 | |
DEF 14A DEF 14A N/A | March 31, 2023 | March 31, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 07, 2022 | 2022 | |
DEF 14A DEF 14A 2022 N/A | January 18, 2022 | February 28, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 01, 2021 | May 12, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 09, 2020 | May 21, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 02, 2019 | May 13, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 05, 2018 | April 05, 2018 | 2018 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.